Cellebrite DI Ltd. $CLBT Shares Sold by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC lessened its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 14.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 564,836 shares of the company’s stock after selling 92,647 shares during the period. Motley Fool Wealth Management LLC’s holdings in Cellebrite DI were worth $10,184,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. increased its position in Cellebrite DI by 293.3% in the 4th quarter. Fox Run Management L.L.C. now owns 70,742 shares of the company’s stock valued at $1,275,000 after acquiring an additional 52,756 shares during the period. LPL Financial LLC increased its position in Cellebrite DI by 15.1% in the 4th quarter. LPL Financial LLC now owns 168,341 shares of the company’s stock valued at $3,035,000 after acquiring an additional 22,054 shares during the period. Clearbridge Investments LLC increased its position in Cellebrite DI by 56.3% in the 4th quarter. Clearbridge Investments LLC now owns 713,214 shares of the company’s stock valued at $12,859,000 after acquiring an additional 256,876 shares during the period. Capital International Investors acquired a new position in Cellebrite DI in the 4th quarter valued at about $41,073,000. Finally, Goldman Sachs Group Inc. increased its position in Cellebrite DI by 34.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 264,918 shares of the company’s stock valued at $4,776,000 after acquiring an additional 67,280 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on CLBT. DA Davidson began coverage on Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC dropped their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Price Performance

CLBT opened at $12.98 on Wednesday. The stock has a market cap of $3.24 billion, a P/E ratio of 46.36, a P/E/G ratio of 1.66 and a beta of 1.17. The stock’s 50 day simple moving average is $13.27 and its 200 day simple moving average is $15.12. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98.

Insider Buying and Selling at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive owned 440,101 shares in the company, valued at $5,620,089.77. This represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 13,269 shares of company stock valued at $169,592. Corporate insiders own 5.70% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.